We envision a future where people stay healthy for life.
Rejuvenate Biomed is a Belgian clinical-stage biomedical company founded in 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical Companies of Johnson & Johnson. In seven years, Ann has built a team of twenty well-experienced drug development experts, enthusiastically engaged to make a difference in the longevity field. Rejuvenate Biomed's team has made exceptional progress by maturing the business to a clinical-stage company. By using its proprietary platforms, AI-enabled CombinAgeTM and in vivo C. elegans CelegAgeTM, Rejuvenate Biomed is generating multiple assets in the drug development pipeline, with lead RJx-01 currently in clinical Phase 2.
-
May 2025
Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
-
October 2024
Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia
-
August 2024
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools
-
February 2024
Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
-
October 2023
First clinical trial successfully completed
In this successful Phase 1b trial, RJx-01 met all primary and secondary endpoints
-
July 2023
Introduction of CelegAge
Proprietary and validated in vivo C. elegans drug discovery platform
-
May 2023
Team expands to 14 innovators
-
March 2023
Introduction of CombinAge
Proprietary and validated AI-enabled in silico drug discovery platform
-
May 2022
Ajit Shetty, PhD, appointed as Chair of the Board of Directors
-
April 2022
Move to new office and lab at Health Campus, Diepenbeek
-
March 2022
First clinical trial with RJx-01 initiated
-
October 2021
€ 15.7 million Series B financing round secured
-
March 2021
€ 3.2 million Series A financing round secured
-
August 2019
€ 1.16 million non-dilutive VLAIO funding
-
February 2019
Key research collaboration with Marco Sandri, MD, PhD
Professor at the Venetian Institute of Molecular Medicine
-
January 2019
Key research collaboration with Rafael de Cabo, MD, PhD
Professor at the NIA's Translational Gerontology Branch
-
August 2018
€ 460,000 non-dilutive VLAIO funding
-
November 2017
Seed investment in place
-
October 2017
Rejuvenate Biomed was founded